Mergers and Acquisitions

Novartis announced on Jan. 5, 2016 that the company is collaborating with Qualcomm to develop cloud-based technology for COPD patients.

Shire’s acquisition of Baxalta creates a leading company for rare disease drugs.

Charles River Laboratories entered into a definitive agreement to acquire WIL Research.

Takeda Pharmaceuticals announced the acquisition of a biopharmaceuticals manufacturing plant in Minnesota.

Corporate restructurings, regulatory initiatives, and biosimilars will shape biopharma development in 2016.

GlaxoSmithKline acquires Bristol-Meyers Squibb’s late-stage HIV R&D assets.

Charles River Laboratories announces the acquisition of Oncotest GmbH.

As a result of the acquisition, Merck will have access to Harrisvaccine’s proprietary RNA Particle technology production platform.

AstraZeneca has agreed to acquire ZS Pharma for $2.7 billion, according to a press release from AstraZeneca. 

Abenza acquired biopharmaceutical CDMO PacificGMP and expanded the company’s San Diego facility.

The acquisition will give IDT Biologika access to the veterinary vaccines market.

Charles Rivers strengthens its endotoxin testing and bacterial identification detection capabilities with the addition of Celsis’ products.

According to Sartorius Stedim Biotech, this acquisition expands its service offering for process development.

Kythera announces that it entered into a definitive agreement to be acquired by Allergan for $2.1 billion.

The Irish company Endo International announced that it would acquire Par Pharmaceutical for $8.05 billion.

Alexion announces it will expand its rare disease pipeline with a definitive agreement to acquire Synageva.

The acquisition expands Sartorius Stedim Biotech’s service portfolio.

Pall’s acquisition of BioSMB from Tarpon Biosystems expands its downstream continuous processing offerings.

Patheon cites expanded API services with acquisition of IRIX Pharmaceuticals.

Thermo Fisher Scientific adds Advanced Scientific’s custom single-use systems and equipment to its bioprocessing offerings.

Roivant Neurosciences acquired GlaxoSmithKline’s selective 5-HTC receptor antagonist for the treatment of various neurological disorders, specifically Alzheimer’s disease.

Merck announced that it acquired OncoEthix, a biotechnology company specializing in oncology drug development, for up to $375 million.

Roche will use Dutalys’ DutaMab technology for the engineering of bispecific therapeutic antibodies.

Roche will use Dutalys’ DutaMab technology for the engineering of bispecific therapeutic antibodies.Roche Acquires Bispecific Antibody Developer Dutalys

Fujifilm Diosynth Biotechnologies announced the completion of the acquisition of Kalon Biotherapeutics, a company that specializes in advanced biologics development manufacturing.

The acquisition will enhance Merck's "superbug" medication portfolio.Merck announced Dec. 8, 2014 that it would acquire Cubist Pharmaceuticals for a total transaction value of approximately $9.5 billion, including a little over $1 million in debt. The deal will add to Merck’s portfolio of drugs treating antibiotic-resistant bacteria, such as Cubist’s antibiotic Cubicin (daptomycin for injection), the only approved once-a-day therapy for both Staphylococcus aureus bacteremia and complicated skin and skin structure infections.

MedImmune enters into an agreement to acquire the image analysis and data mining company.

Acorda Therapeutics acquired Civitas Therapeutics for $525 million, giving Acorda all the rights to CVT-301, a Phase III candidate for off episodes of Parkinson?s disease.

PCI's acquisition of Biotech Services International expands the packaging services provider's presence in Europe.

DPT Laboratories acquired Media Pharmaceuticals' Lakewood, New Jersey facilities, providing space for aseptic processing suites and filling equipment.